High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: First results from the randomized CELSG phase III CML 11 "istahit" study

Haematologica

Volumn 95, Issue 6, 2010, Pages 908-913

  Petzer, Andreas L ^a,b   Wolf, Dominik ^a   Fong, Dominic ^a   Lion, Thomas ^c   Dyagil, Irina ^d   Masliak, Zvenyslava ^e   Bogdanovic, Andrija ^f   Griskevicius, Laimonas ^g   Lejniece, Sandra ^h   Goranov, Stefan ⁱ   Gercheva, Liana ^j   Stojanovic, Aleksandar ^k   Peytchev, Dontcho ^l   Tzvetkov, Nikolay ^m   Griniute, Rasa ⁿ   Oucheva, Radka ^o   Ulmer, Hanno ^a   Kwakkelstein, Marthin ^p   Rancati, Francesca ^q   Gastl, Guenther ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hospital Barmherzige Schwestern Linz   (Austria)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^d RC Radiation Medicine   (Ukraine)

^e Hematology Department of the Academy of Medical Sciences of Ukraine   (Ukraine)

^f CLINICAL CENTER OF SERBIA   (Serbia)

^g VILNIUS UNIVERSITY   (Lithuania)

^h National Center of Haematology   (Latvia)

ⁱ UNIVERSITY HOSPITAL ST GEORGE   (Bulgaria)

^j UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^k Clinical Centre Skopje   (Macedonia)

^l National Center of Haematology and Transfusiology   (Bulgaria)

^m Cardiology Clinic Professor Kiril Chichovski   (Bulgaria)

ⁿ KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^o UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^p NOVARTIS PHARMA AG   (Switzerland)

^q Novartis   (United States)

more..

Author keywords

Chronic phase cml; High dose imatinib; Phase iii study

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; REMISSION INDUCTION; YOUNG ADULT;

EID: 77953208869     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013979     Document Type: Article

References (20)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
3. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI57 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood. 2008; 112(11):186a.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14): 1031-7.
5. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose escalation of imatinib mesylate can over-come resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101(2):473-5.
6. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood. 2003(1);102:83-6.
7. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873-8.
8. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, et al. High dose imatinib in newly diagnosed chronicphase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754-9.
9. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-63.
10. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112(10):3965-73.
11. Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukaemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315-21.
12. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Caner Res. 2005;11(9):3425-32.
13. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6):1809-20.
14. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of" real-time" quantitative reverse transcriptase plymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cacner Program. Leukemia. 2003;17(12): 2318-57.
15. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood.2006;108(1):28-37.
16. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-30.
17. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-8.
18. Cortes J, Baccarani M, Guilhot F, et al. A phase III, randomized, open-label study of 400mg versus 800mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood. 2008;112(11):335a.
19. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, et al. A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study. Blood. 2009;113(19):4497-504.
20. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk "chronic granulocytic leukemia. Blood. 1984;63(4):789-99.